# Special Issue

# Epigenetic Regulation of Anti-tumor Immune Response

### Message from the Guest Editor

Evasion from immunosurveillance by cancer cells is a major cancer hallmark, and restoration of immunosurveillance has been demonstrated as an effective anti-tumor strategy. For example, immune checkpoint inhibitors have achieved remarkable responses. Recent studies showed that epigenetic aberrations contribute to downregulation of anti-tumor immune responses. Epigenetic targeting has shown promising effects by inducing robust anti-tumor immune response, alone or in combination with immune checkpoint inhibitors. This Special Issue is focused on the study of epigenetic regulators of anti-tumor immune response, as well as epigenetic-based therapeutics for cancer treatment. We will consider review, research, or method manuscripts with a broad interest in these areas.

### Guest Editor

Dr. Qin Yan

Department of Pathology, Yale University School of Medicine, New Haven, CT 06510-3128, USA

### Deadline for manuscript submissions

closed (31 January 2019)

**Epigenomes**

**an Open Access Journal by MDPI**

**Impact Factor 3.5**
**CiteScore 4.4**
**Indexed in PubMed**

mdpi.com/si/15070

*Epigenomes*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
epigenomes@mdpi.com

mdpi.com/journal/epigenomes

# Epigenomes

an Open Access Journal by MDPI

Impact Factor 3.5
CiteScore 4.4
Indexed in PubMed

mdpi.com/journal/epigenomes

MDPI

# About the Journal

## Message from the Editor-in-Chief

In the past years the growth of the epigenetic field has been outstanding, from here the need of a journal where to centralize all new information on the subject. The term epigenetics is now broadly used to indicate changes in gene functions that do not depend on changes in the sequence of DNA. *Epigenomes* covers all areas of DNA modification from single cell level to multicellular organism as well as the epigenetics on human pathologies and behavior.
*Epigenomes* (ISSN 2075-4655) is a fully peer-reviewed publication outlet with a rapid and economical route to open access publication. All articles are peer-reviewed and the editorial focus is on determining that the work is scientifically sound rather than trying to predict its future impact.

## Editor-in-Chief

Prof. Dr. Ernesto Guccione
Icahn School of Medicine at Mount Sinai, Hess Center for Science and Medicine, New York, NY 10029, USA

## Author Benefits

**High Visibility:**

indexed within Scopus, ESCI (Web of Science), PMC, PubMed, Embase, PubAg, CAPlus / SciFinder, and other databases.

**Journal Rank:**

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Biochemistry, Genetics and Molecular Biology (miscellaneous))

**Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25.5 days after submission; acceptance to publication is undertaken in 3.8 days (median values for papers published in this journal in the second half of 2025).